Assistance Publique Hopitaux De Paris
Verified site
Paris, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
Higher-risk Myelodysplastic Syndrome (HR-MDS) is a condition where the bone marrow makes abnormal blood cells, leading to low blood counts and a higher chance of turning into leukemia. In this trial, participants receive a combination of bexmarilimab, given by IV infusion, together with the chemotherapy drug azacitidine. Some participants receive a matching placebo plus azacitidine instead of the study drug.
The study aims to find the best dose of bexmarilimab when used with azacitidine. Participants are randomly assigned to one of the two groups, and neither the participants nor the doctors know which group they are in (double‑blind). Treatments are given in cycles that repeat every few weeks for several months, with regular clinic visits for infusions and safety checks.
During the trial, doctors watch for how well the blood counts improve and for any side effects, using standard criteria that describe remission and serious adverse events. Blood samples are taken to see how the drug behaves in the body, and patients are asked about their quality of life, such as need for transfusions or hospital stays.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
13 criteria
19 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Paris, France
Poitiers, France
Villejuif, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an investigational medicine that is given through a vein (intravenous infusion). It is being studied as a possible treatment for higher‑risk myelodysplastic syndromes, a group of blood disorders. In this trial, the drug is combined with another therapy to see if it can improve how well the blood cells work and to assess its safety for patients who have not received prior treatment for this condition. Researchers are looking at how the drug behaves in the body, how it affects the disease, and whether patients can tolerate it well.
is a chemotherapy‑type medication that is already approved for treating certain blood disorders, including myelodysplastic syndromes. It is given by injection under the skin or into a vein and works by helping abnormal blood‑forming cells mature into normal cells. In this study, azacitidine is used together with the experimental drug Bexmarilimab to determine whether the combination can provide better outcomes for patients who have not yet been treated for higher‑risk myelodysplastic syndromes. The trial evaluates how well the combination works and monitors any side effects.
This medication is a sterile salt‑water solution that is given through an intravenous (IV) line, allowing it to enter directly into the bloodstream. It is a well‑established product used worldwide to replace fluids and electrolytes, and it is listed in standard medical references as a basic IV fluid. In this trial it serves as a placebo, meaning it does not treat the disease but provides a comparison for the active drug. It belongs to the class of electrolyte solutions.
Bexmarilimab is administered by IV infusion at a dose of 3 mg per kilogram of body weight, delivering the drug straight into the blood. It is an investigational, orphan‑designated monoclonal antibody currently being studied in clinical trials and reported in recent medical literature. The drug is being tested for higher‑risk myelodysplastic syndrome, a blood disorder, and works by blocking the CD47 protein so that the immune system can better recognize and destroy abnormal blood cells. It is classified as a humanized IgG4 monoclonal antibody and an immune‑checkpoint inhibitor.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.